Definitive Proxy Filed for Remix Reverse Merger: Existing Passage Bio Holders to Own Just 6%
PASG sits 47% above its 52-week low of $3.29 on elevated volume (1.8× avg).
Summary
The definitive proxy statement confirms existing stockholders will be diluted to just 6% ownership in the combined company after the reverse merger with Remix Therapeutics, though a higher-than-expected net cash position of $10.9 million could slightly improve that figure.
Key Events · M&A and Partnerships · PASG
-
Reverse Merger Ownership Split Confirmed
Existing Passage Bio stockholders will own approximately 6% of the combined company, Remix equityholders 65%, and Concurrent Financing investors 29%, based on a Remix equity value of $226 million and Passage Bio valuation of $20 million.
-
Net Cash Position Higher Than Expected
Passage Bio Net Cash at closing is now anticipated to be approximately $10.9 million, versus the $5.0 million assumption in the exchange ratio formula, which could modestly increase existing stockholders' ownership percentage.
-
Contingent Value Rights Offer Partial Recovery
Existing stockholders will receive one CVR per share, entitling them to 80% of GM1 program payments (through July 31, 2028) and 100% of MLD program payments (through December 31, 2027) from Gemma Biotherapeutics, though these may expire worthless.
-
Special Meeting and Closing Timeline
The special meeting date is not yet set, but the merger is expected to close in Q4 2026, subject to stockholder approval of the Nasdaq Stock Issuance, Reverse Stock Split, and Charter proposals.
Analysis · PASG · Life Sciences
This Amendment No. 2 to the S-4 serves as the definitive proxy statement/prospectus for the reverse merger with Remix Therapeutics. It confirms the harsh economics for existing Passage Bio stockholders: they will own approximately 6% of the combined company, while Remix equityholders get 65% and Concurrent Financing investors get 29%. The filing also reveals that Passage Bio's net cash at closing is now expected to be $10.9 million, higher than the $5 million assumption in the exchange ratio formula, which could slightly improve the ownership percentage for existing holders. The CVR agreement offers a potential lifeline — 80% of GM1 payments and 100% of MLD payments from Gemma Biotherapeutics — but these are contingent and may expire worthless. The special meeting date is still blank, but the merger is expected to close in Q4 2026.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PASG was trading at $4.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.5M. The 52-week trading range was $3.29 to $20.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.